UnitedHealth Group’s second-quarter 2026 print — $5.5 billion in profit on $112 billion in revenue — landed as the largest single-quarter earnings figure the managed care comp set produced in H1. The same quarter a year earlier had been $3.4 billion. At the midpoint of 2026, UNH had booked $11.8 billion in profit, up from $9.7 billion in H1 2025. Leerink Partners’ senior research partner Whit Mayo called it “a profound amount of improvement.”

That is the anchor of a broader H1 story: every major managed care insurer that reported Q2 2026 posted a profit, and most raised full-year guidance. The 2025 MLR-shock chapter that ran across the industry appears to have closed inside two quarters. It closed unevenly.

Centene ran the sharpest swing. Q2 2026 profit of roughly $1.1 billion, against a prior-year loss. Centene raised 2026 adjusted EPS guidance to greater than $4.80, up from a prior $3.40, its second beat-and-raise of the year, but that outlook is still meaningfully below the $7.17 the company posted in 2024 and the $6.68 in 2023 before the 2025 disruption hit. The recovery is real; the recovery is not yet a return to trend.

The segment-level MLR figures make the operational read cleaner. Centene’s commercial MLR ran 79.2% in Q2, down from 90.6% a year earlier — a swing driven by ACA repricing for the 2026 plan year and what CFO Drew Asher described on the call as a “tapering” medical trend. Medicaid MLR came in at 93.9% (from 94.9%); Medicare MLR at 89.5% (from 90.9%). All three segments improved. Only one — commercial — improved dramatically.

The rest of the comp set landed where the Street mostly expected. Elevance posted $1.7 billion in Q2 profit; Cigna, $1.5 billion; CVS Health, just under $3 billion on $106.1 billion in revenue. CVS’s H1 profit reached $5.9 billion, more than double the $2.8 billion in H1 2025.

Humana is the divergence worth naming. Q2 profit of $694 million, up from $545 million a year earlier: a real improvement but modest against the comp set. The Q2 insurance-segment benefit ratio landed at 91.2%, tracking the just-above-91% forecast the company had set going in. Individual Medicare Advantage membership grew roughly 25% year over year, driving consolidated Q2 revenue to $40.87 billion.

What it did not do is raise full-year guidance. Humana affirmed FY 2026 adjusted EPS guidance of at least $9 and held its full-year insurance-segment benefit ratio guidance at 92.75% ± 25 basis points. The adjusted EPS figure implies a year-over-year decline from 2025 levels because of the Medicare Advantage Star Ratings headwind compressing quality bonus payments through 2026. Investors are now looking through 2026 toward multi-year margin improvements rather than pricing this year’s beat-and-raise cycle into the shares.

Two threads for the next print worth putting on the watch list.

Medicaid is not out. Centene’s Medicaid MLR at 93.9% is still north of most historical norms for the segment. The insurers are describing Q2 as the trough. Whether it turns out to have been the trough depends on how the work-requirements roll-out that goes national on January 1, 2027 lands on membership and acuity. Any Q4 2026 or Q1 2027 print in the Medicaid-heavy names (Centene, Molina, Elevance’s Medicaid book) is where that shows up.

The MA bid cycle for 2027 is the other watch item. Humana’s decision to hold guidance rather than raise is one signal; the company’s Q2 disclosure that it is planning further MA market exits for 2027 is another. The AEP window for 2027 plans opens in October 2026; the disclosures in Q3 earnings calls about bid discipline, geographic footprint, and Star Ratings litigation will set the frame for the 2027 comp-set narrative.

The clean read on H1 2026 is that the industry priced its way out of the 2025 shock, repositioned membership toward more profitable enrollees, and got operating trend to stabilize. The messier read — Humana holding guidance, Medicaid MLRs still elevated, Star Ratings and work requirements still ahead — is the reason Q3 earnings will get read for what they say about 2027 rather than what they say about the back half of 2026.

This is analysis, not investment advice. Continuum does not make recommendations to buy or sell securities.